ReviewCureus2026
Irritable Bowel Syndrome: Contemporary Management Approaches, Limitations, and Future Directions.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction characterized by recurrent abdominal pain associated with altered bowel habits in the absence of structural disease. Despite its high prevalence and substantial impact on quality of life, healthcare utilization, and long-term symptom burden, IBS management remains challenging because of its heterogeneous pathophysiology and variable treatment response. Current evidence supports a multifactorial model involving altered motility, visceral hypersensitivity, dysregulated brain-gut signaling, mucosal immune activation, microbiome changes, and intestinal barrier dysfunction, all of which contribute to the complexity of care. This narrative review summarizes contemporary management approaches for IBS, including dietary interventions, psychological therapies, pharmacologic treatments, biomarker-guided strategies, digital health technologies, and integrated care models. Particular attention is given to the low fermentable oligosaccharide, disaccharide, monosaccharide, and polyol (FODMAP) diet, soluble fiber, cognitive behavioral therapy (CBT), gut-directed hypnotherapy, subtype-specific pharmacologic agents, and emerging digital therapeutics that improve access to behavioral and self-management support. Although the literature demonstrates meaningful benefit across several treatment domains, important limitations remain, including short follow-up duration, lack of mechanistic stratification, inconsistent biomarker validation, and uncertainty regarding long-term treatment sequencing and personalization. Future progress in IBS care will likely depend on precision-oriented approaches that integrate clinical phenotyping, biologic markers, and multimodal treatment pathways tailored to individual patients. Continued emphasis on pragmatic trials, real-world implementation, and mechanism-based care models will be essential to improve outcomes and reduce the overall burden of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.